1. Home
  2. ACLX

as 10-08-2025 11:39am EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Founded: 2015 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 4.4B IPO Year: 2022
Target Price: $114.75 AVG Volume (30 days): 515.6K
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.43 EPS Growth: N/A
52 Week Low/High: $47.86 - $107.37 Next Earning Date: 11-06-2025
Revenue: $56,979,000 Revenue Growth: -60.63%
Revenue Growth (this year): -59.13% Revenue Growth (next year): 210.71%

Stock Insider Trading Activity of Arcellx Inc. (ACLX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Gilson Michelle ACLX CHIEF FINANCIAL OFFICER Oct 6 '25 Sell $86.22 1,064 $91,733.29 13,830
Gilson Michelle ACLX CHIEF FINANCIAL OFFICER Oct 3 '25 Sell $86.00 4,882 $419,869.58 13,830
Heery Christopher ACLX CHIEF MEDICAL OFFICER Sep 30 '25 Sell $81.40 21,034 $1,709,722.59 16,358
Heery Christopher ACLX CHIEF MEDICAL OFFICER Sep 29 '25 Sell $80.16 73 $5,851.68 16,358

Share on Social Networks: